Onsdag 30 Oktober | 09:27:57 Europe / Stockholm

Kalender

Tid*
2025-02-27 - Bokslutskommuniké 2024
2024-08-16 - Kvartalsrapport 2024-Q2
2024-03-28 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2023-03-31 - Årsstämma
2023-02-27 - Bokslutskommuniké 2022
2022-08-12 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2022-03-31 - Årsstämma
2022-02-28 - Bokslutskommuniké 2021
2021-08-13 - Kvartalsrapport 2021-Q2
2021-05-17 - Split NXTMS 100:1
2021-04-30 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2021-04-29 - Årsstämma
2021-03-01 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2020-08-14 - Kvartalsrapport 2020-Q2
2020-04-01 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2020-02-28 - Bokslutskommuniké 2019
2019-11-11 - Extra Bolagsstämma 2019
2019-08-16 - Kvartalsrapport 2019-Q2
2019-03-26 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2019-03-25 - Årsstämma
2019-03-04 - Bokslutskommuniké 2018
2018-11-26 - Split NXTMS 30:1
2018-11-21 - Extra Bolagsstämma 2018
2018-08-16 - Kvartalsrapport 2018-Q2
2018-03-29 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2018-03-28 - Årsstämma
2018-02-28 - Bokslutskommuniké 2017
2017-08-16 - Kvartalsrapport 2017-Q2
2017-03-29 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2017-03-28 - Årsstämma
2017-02-28 - Bokslutskommuniké 2016
2017-02-17 - Extra Bolagsstämma 2017
2016-08-17 - Kvartalsrapport 2016-Q2
2016-04-01 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2016-03-31 - Årsstämma
2016-02-29 - Bokslutskommuniké 2015
2015-12-22 - Extra Bolagsstämma 2015
2015-08-20 - Kvartalsrapport 2015-Q2
2015-04-01 - X-dag ordinarie utdelning NXTMS 0.00 SEK
2015-03-31 - Årsstämma
2015-02-26 - Bokslutskommuniké 2014

Beskrivning

LandFinland
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Nexstim är verksamt inom medicinteknik. Bolaget har utvecklat en icke-invasiv teknik för hjärnstimulering som kallas SmartFocus®. Det är en navigerad magnetisk stimuleringsteknik (nTMS) med 3D-navigering som ger inriktning av TMS till det specifika området av hjärnan. Tekniken är avsedd för behandling av svår depression och kronisk neuropatisk smärta. Bolaget grundades år 2000 och har sitt huvudkontor i Helsingfors.
2024-06-17 11:45:00

Company announcement, Helsinki, 17 June 2024 at 12:45 PM (EEST)

Nexstim Plc: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act

Nexstim Plc (NXTMH:HEX) (”Nexstim” or ”Company”) has received a notification pursuant to chapter 9, section 5 of the Securities Market Act from Leena Niemistö on 17 June 2024.

The notification is based on the amendment to the Securities Market Act effective April 19, 2024, requiring shareholders to notify the target company and the Financial Supervisory Authority of their ownership and voting shares no later than two months after the enactment of this law if the shareholder's stake in the target company is at least five percent at the time the law takes effect and such share has not been previously disclosed.

Total position of person subject to the notification obligation:

 % of shares and voting rights (total of 7.A)% of shares and voting rights through financial instruments (total of 7.B)Total of both in %
(7.A + 7.B)
Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached

15.37515*


0.296218**


13.13344***


8,103,096
Positions of previous notification (if applicable)    

Notified details of the resulting situation on the date on which the threshold was crossed:

A: Shares and voting rights

Class/type of shares
ISIN code (if possible)
Number of shares and voting rights% of shares and voting rights
 Direct
(SMA 9:5)
Indirect
(SMA 9:6 ja 9:7)
Direct
(SMA 9:5)
Indirect
(SMA 9:6 ja 9:7)
FI400050681117,7991,022,4160.26308215.11206
SUBTOTAL A1,040,21515.37515

B: Financial instruments according to SMA 9:6a

Type of financial instrumentExpiration dateExercise / Conversion PeriodPhysical or cash settlementNumber of shares and voting rights% of shares and voting rights
Stock options 2023H15.12.2029  12,0000.14809
Stock options 2024H15.12.2030  12,0000.14809
   SUBTOTAL B24,0000.29618

Information in relation to the person subject to the notification obligation:

Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:

Name        % of shares and voting rights % of shares and voting rights through financial instruments Total of shares, voting rights, and financial instruments
Leena Niemistö 0.2630820.2961841,799
Kaikarhenni Oy 15.112060 1,022,416

Additional information:

Leena Niemistö holds 55% of Kaikarhenni Oy. First disclosure of holdings regarding the Securities Market Act effective April 19, 2024.

*percentage of shares and voting rights calculated based on total number of shares, 6,765,562.

** percentage of shares and voting rights calculated based on diluted total number of shares, 8,103,096.

*** total percentage of shares (7.A + 7.B) calculated based on diluted total number of shares, 8,103,096.

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

The Company’s Certified Advisor is Carnegie Investment Bank AB (publ).

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.

Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com